Pathological Mechanism and Treatment of Calcified Aortic Stenosis.

Autor:	Chen SY; Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Nanjing 210006, China., Kong XQ; Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Nanjing 210006, China.; Department of Cardiology, Nanjing Heart Centre, Nanjing, China., Zhang JJ; Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Nanjing 210006, China.; Department of Cardiology, Nanjing Heart Centre, Nanjing, China.
Jazyk:	angličtina
Zdroj:	Cardiology in review [Cardiol Rev] 2024 Jul-Aug 01; Vol. 32 (4), pp. 320-327. Date of Electronic Publication: 2024 Jun 06.
DOI:	10.1097/CRD.0000000000000510
Abstrakt:	Calcified aortic stenosis (AS) is one of the most common valvular heart diseases worldwide, characterized by progressive fibrocalcific remodeling and thickening of the leaflets, which ultimately leads to obstruction of blood flow. Its pathobiology is an active and complicated process, involving endothelial cell dysfunction, lipoprotein deposition and oxidation, chronic inflammation, phenotypic transformation of valve interstitial cells, neovascularization, and intravalvular hemorrhage. To date, no targeted drug has been proven to slow down or prevent disease progression. Aortic valve replacement is still the optimal treatment of AS. This article reviews the etiology, diagnosis, and management of calcified aortic stenosis and proposes novel potential therapeutic targets. Competing Interests: Disclosure: All authors have no conflicts of interest to report. (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu